PLYX

Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing small molecule and gene therapy treatments for lysosomal storage disorders (LSDs), which are rare inherited metabolic diseases. The company’s pipeline includes therapies aimed at addressing the genetic and pathological features of LSDs, with a particular emphasis on pediatric populations. Polaryx operates in the United States and is preparing to conduct clinical trials for its lead drug candidate, PLX-200, targeting conditions such as Krabbe Disease and Late Infantile Neuronal Ceroid Lipofuscinosis.